Bergen, Norway, 11 May 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce that pre-clinical COVID-19 data has been presented at Virtual Immunology 2021, which is taking place from 10-15 May 2021. The poster presentation illustrates findings from a pre-clinical study conducted by BerGenBio’s scientific … Read more
Bergen, Norway, 7 May 2021 – BerGenBio ASA (the “Company”) (OSE:BGBIO) announced that the Board of Directors has granted share options to employees. The annual general meeting in the Company 19 March 2021 approved the share option program and authorised the board of directors of the Company to issue shares to the Company’s employees as part … Read more
Bergen, Norway, 5 May 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, will be announcing its results for the first quarter 2021 on Wednesday 19 May 2021. A webcast presentation by BerGenBio’s senior management team will take place at 10:00 am CET. The live … Read more
Bergen, Norway, 30 April 2021 – Reference is made to the stock exchange notice published by BerGenBio ASA (the “Company”) (OSE: BGBIO) on 23 April 2021 where the Company announced that the board of directors of the Company had resolved to increase the Company’s share capital in connection with the exercise of options pursuant to the Company’s … Read more
Bergen, Norway, 28 April 2021 - BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce that its abstract has been accepted for a poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place online from 4-8 June 2021. Abstract titles have been announced online … Read more
Bergen, Norway, 26 April 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce that a poster presentation on pre-clinical COVID-19 data has been accepted for presentation at Virtual Immunology 2021, taking place from 10-15 May 2021. Virtual Immunology 2021 is the 104[th] annual conference … Read more
Bergen, Norway, 23 April 2021; The Board of Directors in BerGenBio ASA (the “Company”) (OSE: BGBIO) have, to fulfil the Company’s obligations under the share option agreements and in accordance with the authorization granted by the general meeting on 19 March 2021, resolved to increase the Company’s share capital by NOK 6,617.30 by issuance of … Read more
Bergen, Norway, 21[st] April 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce that BerGenBio CEO Mr. Richard Godfrey is presenting at the following virtual conference: Arctic Securities Biotech Webinar, April 22, 2021 Live presentation at 14.05hrs CET The presentation will … Read more
Day 29 follow-up of last patient enrolled has now occurred in BGBC020 and ACCORD2_002 Data receipt is ongoing and evaluation of efficacy data is underway Exploratory analyses are looking to define subsets of patients with baseline markers indicative of increased disease severity with the potential for greater benefit Bemcentinib was well tolerated throughout both studies, … Read more
Dag 29 oppfølgning av siste rekrutterte pasient har nå skjedd i BGBC020 og ACCORD2-002 Innhentning av data pågår, og evaluering av effektdata er påbegynt Undersøkende analyser ønsker å definere undergrupper av pasienter med baseline markører som indikerer økt alvorlighetsgrad av sykdommen, med potensial for større nytte for pasienter Bemcentinib ble godt tolerert i begge studiene, … Read more
soug@oncoinvent.com
Oystein Soug has over 15 years of experience in biotechnology, holding several management positions. Most recently, Mr. Soug was CEO of Arxx Therapeutics, where he led the company to initiate the clinical programme and was responsible for the merger with Dutch pharma company Oxitope Pharma to create Calluna Pharma. Prior to Arxx, he served as CFO and then CEO of Targovax, an Oslo listed biotechnology company, which went public during Mr. Soug’s tenure. Mr. Soug started his career in biotech as CFO of Oslo-listed radiopharmaceutical company Algeta. During this period, the company conducted a successful phase 3 trial, launched its radium-223 based prostate cancer drug Xofigo® and out-licensed the drug. Mr. Soug co-led the sale of the company to Bayer in 2014.
Mr. Soug holds an MSc in Economics and
Financial Markets from Universität St. Gallen in Switzerland in 1997
mansson@oncoinvent.com
Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.
Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.